FORUM REVIEW ARTICLE

GPx4, Lipid Peroxidation, and Cell Death: Discoveries, Rediscoveries, and Open Issues

Matilde Maiorino,¹ Marcus Conrad,² and Fulvio Ursini¹

Abstract

Significance: Iron-dependent lipid peroxidation is a complex oxidative process where phospholipid hydroperoxides (PLOOH) are produced in membranes and finally transformed into a series of decomposition products, some of which are endowed with biological activity. It is specifically prevented by glutathione peroxidase 4 (GPx4), the selenoenzyme that reduces PLOOH by glutathione (GSH). PLOOH is both a product and the major initiator of peroxidative chain reactions, as well as an activator of lipoxygenases. α -Tocopherol both specifically breaks peroxidative chain propagation and inhibits lipoxygenases. Thus, GPx4, GSH, and α -tocopherol are integrated in a concerted anti-peroxidant mechanism.

Recent Advances: Ferroptosis has been recently identified as a cell death subroutine that is specifically activated by missing GPx4 activity and inhibited by iron chelation or α -tocopherol supplementation. Ferroptosis induction may underlie spontaneous human diseases, such as major neurodegeneration and neuroinflammation, causing an excessive cell death. The basic mechanism of ferroptosis, therefore, fits the features of activation of lipid peroxidation.

Critical Issues: Still lacking are convincing proofs that lipoxygenases are involved in ferroptosis. Also, unknown are the molecules eventually killing cells and the mechanisms underlying the drop of the cellular anti-peroxidant capacity.

Future Directions: Molecular events and mechanisms of ferroptosis to be unraveled and validated on animal models are GPx4 inactivation, role of GSH concentration, increased iron availability, and membrane structure and composition. This is expected to drive drug discovery that is aimed at halting cell death in degenerative diseases or boosting it in cancer cells. *Antioxid. Redox Signal.* 29, 61–74.

Keywords: glutathione, peroxidation inhibiting protein, PHGPx, ferroptosis, tocopherol

Introduction

THE SELENOPEROXIDASE glutathione peroxidase 4 (GPx4), discovered in 1982 as a cytosolic “peroxidation inhibiting protein” (110), is seen today as a specific target of new pharmacological treatments aiming at activating or inhibiting cell death in cancer or degenerative diseases, respectively (36, 123). Since a comprehensive review on biochemistry and molecular biology of GPx4 has been recently published (69), this review will specifically focus on the relationship between GPx4, iron-dependent lipid peroxidation, and cell death. Indeed, the phenotype resulting from GPx4 silencing or inhibition (Fig. 1) led to identifying a sub-routine

of programmed death (37), and because inhibitors of neither apoptosis nor necroptosis can rescue GPx4-depleted cells, the claim of having identified a novel mechanism seems appropriate. Although the given name “ferroptosis” focuses on the critical role of iron, the involvement of GPx4, reduced glutathione (GSH), and α -tocopherol entails lipid peroxidation as the molecular mechanism executing the death sentence. Notably, the chemical steps of iron-dependent lipid peroxidation leading to ferroptosis recapitulate the features of microsomal lipid peroxidation as originally described by P. Hochstein and L. Ernster more than 50 years ago (50). Consistently, it was the inhibition of microsomal lipid peroxidation that drove the discovery of GPx4 (110).

¹Department of Molecular Medicine, University of Padova, Padova, Italy.

²Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.

FIG. 1. *In vivo* models of tissue-specific GPx4 loss yielding overt phenotypes. Tissues where GPx4 loss was obtained by tissue-specific silencing or whole body deletion produced a specific pathological pattern. Numbers indicate the pertinent references. GPx4, glutathione peroxidase 4. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

At the present level of knowledge, ferroptosis is seen as the final outcome of an imbalance between the rate of the oxidative reactions of lipid peroxidation and the rate of the metabolic pathways supporting the nucleophilic tone of the cell. Consistently, GPx4 activity emerges as a major player in neurodegeneration (17). Since cell death and inflammation are linked by a bi-univocal relationship (83), ferroptosis is a critical player in diseases that are collectively defined as neuro-inflammatory. Paradigmatic examples are Alzheimer (46, 48), Parkinson (8, 45, 49), and Huntington disease (22, 26).

Here, we will summarize the key features of lipid peroxidation describing the progressive achievements of knowledge that paved the road from rancidity of fat to the identification of GPx4 as a pharmacologically relevant target. Still open issues, requiring specifically addressed experimental work will be finally outlined.

Lipid Autoxidation and Peroxidation

Painters and carpenters know from centuries that vegetable oils, containing polyunsaturated fatty acids, harden when exposed to air and are warmed up, producing a film that is the ancestor of the modern polymeric resins. It is also known from centuries that foods, protected from faster microbiological degradation, for example, by salt, undergo a slow degradation process, leading to rancidity. The oxidative nature of these events was first pointed out by De Saussure in 1804 by manometric and gravimetric measurements showing that linseed oil binds oxygen (28). He also discussed the possibility that the oxidative polymerization was the actual mechanism of film formation in vegetable oils hardening. The term “peroxidation” was introduced later to focus on the notion that peroxides—lipid hydroperoxides indeed—are produced. Moreover, in the case of lipid peroxidation of biological membranes, structural constraints contribute to the control of the rate of the basic chemical reactions of autoxidation.

Iron-dependent lipid peroxidation encompasses free radical reactions that can be schematically summarized as: (i) initiation, which includes hydrogen atom abstraction from a phospholipid containing polyunsaturated fatty acid (PL) and

oxygen addition to the phospholipid carbon centered radical ($PL^\bullet$); (ii) chain propagation yielding a phospholipid hydroperoxide (PLOOH) and a new $PL^\bullet$ ($PL^\bullet$); and (iii) arrest, by radical-radical interaction (Fig. 2). Notably, the O–O bond of PLOOH, the major stable (nonradical) product of the reaction, is, indeed, relatively unstable, driving new initiation reactions by decomposition and producing a plethora of small molecules, most frequently of an electrophilic nature (126).

Free radical reactions of lipid peroxidation are, in general, very fast, with a rate constant being in the range of $10^8 M^{-1} s^{-1}$ (2, 77, 126), with the exception of the rate-limiting chain propagation reactions. The H abstraction, indeed, from a methylene carbon of a polyunsaturated fatty acid by a lipid hydroperoxyl radical, forming a new carbon centered radical that propagates the peroxidative chain reaction and a hydroperoxide, occurs with a rate constant in the range of $10^3 M^{-1} s^{-1}$ (13) (Fig. 2). This relatively low rate constant permits the diffusion of phospholipid hydroperoxyl radical ($PLOO^\bullet$) within the membrane and toward the surface (the floating peroxy radical theory) (7). Here, the fast interaction ($\sim 10^6 M^{-1} s^{-1}$) takes place with the redox center of tocopherol (13), located at the water boundary. Thus, tocopherol is the most specific “chain-breaking antioxidant” (14), a concept that, while emphasizing the role in inhibiting chain propagation, limits the preventive antioxidant activity to conditions when lipid peroxidation is initiated by hydroperoxyl radicals. A typical example of the latter is the popular thermal decomposition of azo-initiators (126), which, on the other hand, has no suitable counterpart in biology. Even though recent computational quanto-mechanical analysis argues against the floating peroxy radical theory (38), it seems reasonable assuming that in lipid peroxidation of membranes there must be a relevant trafficking of lipophilic and hydrophilic species from the core to the surface of membranes, where critical pro- and anti-peroxidant events take place.

The discovery of a peroxidation inhibiting protein (P.I.P.) was inspired by an observation coming from the laboratory of P. McCay, showing that, *in vitro*, in the presence of cytosol, GSH completely prevents iron-dependent microsomal lipid peroxidation (43). Neither the “classical” glutathione peroxidase

$X^\bullet + PL \rightarrow XH + PL^\bullet$	INITIATION
$PL^\bullet + O_2 \xrightarrow{(k=10^6 M^{-1} sec^{-1})} PLOO^\bullet$	PROPAGATION
$PLOO^\bullet + PL' \xrightarrow{(k=10^3 M^{-1} sec^{-1})} PLOOH + PL'^\bullet$	
$PLOOH + Fe^{2+} \rightarrow PLO^\bullet + Fe^{3+} + OH^-$	INITIATION
$PLO^\bullet + PL'' \xrightarrow{(k=10^6 M^{-1} sec^{-1})} PLOH + PL''^\bullet$	
$PLO^\bullet, PLOO^\bullet \rightarrow \text{Non-radical products}$	TERMINATION
$\alpha\text{-TOH} + PLOO^\bullet \xrightarrow{(k=10^6 M^{-1} sec^{-1})} PLOOH + \alpha\text{-TO}^\bullet$	CHAIN BREAKING
$\alpha\text{-TO}^\bullet \rightarrow \text{Non-radical products}$	

FIG. 2. Major reactions of iron-dependent lipid peroxidation. PL, PL', and PL'' are distinct membrane phospholipids containing polyunsaturated fatty acid(s); X[•] is a non-specified initiating free radical species; α-TOH is α-tocopherol and α-TO[•] its radical; non-radical products stand for products of chain termination and phospholipid decomposition species; PLOO[•], PLO[•] and PL[•], PL[•], PL[•], stand for different phospholipid radicals; PLOOH is a phospholipid hydroperoxide; and PLOH is a phospholipid alcohol. Initiation refers to both a PLOOH-independent and -dependent mechanism, that is, by an initiating species (X[•]) and by a ferrous iron-mediated decomposition of a PLOOH, yielding a PLO[•]. PLO[•] takes an H from a fatty acid chain esterified to another phospholipid (PL''), which yields a phospholipid radical in the membrane (PL''[•]) and PLOH. Note that the products of the initiation reactions (PL[•], PL[•], PL[•]) are generated by PLOOH independent and/or dependent initiation and by PLOO[•]-mediated propagation. The chain-breaking effect of α-TOH is accounted for by the much faster reaction of PLOO[•] with α-TOH than PL and the relative stability of α-TO[•]. PL'', distinct membrane phospholipids containing polyunsaturated fatty acids; PL[•], phospholipid containing a fatty acid carbon centered radical; PLOH, phospholipid containing a hydroxyl derivative of a fatty acid; PLOOH, phospholipid hydroperoxide, a phospholipid containing a hydroperoxyl derivative of a fatty acid.

(now known as GPx1, E.C.1.11.1.9) nor glutathione transferases, superoxide dismutases (SOD) or catalase, reproduce the effect of cytosol and GSH. To address the catalytic activity on PLOOH, purified P.I.P. was renamed as “Phospholipid Hydroperoxide Glutathione Peroxidase” (PHGPx, E.C. 1.11.1.12) (71, 110), and then systematically filed as the GPx4 gene product (44). In the *in vitro* studies mentioned earlier, the rather simple nature of the mixture of the pro- and anti-peroxidant components—adenine nucleotide, NADPH, GSH, membranes and cytosol, and, in some conditions, α-tocopherol—was already pointing out *per se* an aspect today emerging as a crucial feature of a specific form of programmed cell death (23, 29). Seemingly, lipid peroxidation is sparked by the inactivation of the anti-peroxidant mechanism based on the reduction of PLOO[•] and PLOOH, rather than by a sudden increase of an unknown oxidant.

Notably, to date, other enzymes have been shown to reduce esterified lipid hydroperoxide *in vitro* (namely, GPx3, Peroxiredoxin 6, and GPx7) (10, 34, 119) but apparently none of them could mimic the antioxidant effect of GPx4: reduction of PLOOH in membranes and inhibition of microsomal lipid

peroxidation. This observation complies with the distinct phenotype obtained by individual gene silencing (80, 111, 112), where only that of GPx4 is indispensable (52, 125).

In biological membranes undergoing iron-dependent lipid peroxidation *in vitro*, the reduction of PLOOH into corresponding phospholipid alcohols (PLOH) by GPx4 and GSH (Fig. 3) integrates the antioxidant chain-breaking mechanism of α-tocopherol (Fig. 4). The latter, by scavenging the peroxidation-driving PLOO[•], prevents chain propagation, producing a minute amount of PLOOH that can initiate, in the presence of ferrous iron, a new peroxidative chain reaction (109). The phospholipid alkoxyl radical (PLO[•]) produced starts a new chain reaction by attacking the methylene carbon of a polyunsaturated fatty acid, thus generating a PLOH and a new PL[•]. Remarkably, this reaction is so fast (2) that a competing reaction with a free radical scavenger, such as α-tocopherol, cannot produce any relevant antioxidant protection. It follows that the only way for preventing this initiation is the reduction of the precursor PLOOH (70). In summary, GPx4, GSH, and α-tocopherol are players of a concerted anti-peroxidant machinery where the synergy between one-

FIG. 3. Scheme of GPx4 catalysis (A) and analytic Connolly's surface distribution of the semireduced catalytic intermediate (B). In (A), the reaction of GPx4 that is linked to the peroxidase's vital function is reported. Substrates (phospholipid hydroperoxides, PLOOH, GSH) and products (phospholipid alcohols, PLOH, GSSG, H₂O) are indicated. E, F, and G are the reduced, oxidized, and semireduced catalytic forms of GPx4, respectively. See Orian *et al.* (81) for details. In (B), the GPx4 analytic Connolly's surface distribution of the semireduced intermediate G is depicted in blue, except for the redox-active selenium that is orange. The amino acids interacting with GSH are indicated as balls and sticks. GSH is red. Within GSH, the three nitrogens are blue and sulfur is yellow. Note that the intermediate contains a mixed selenadisulfide between the peroxidase and GSH. (The model was kindly provided by Dr. Giorgio Cozza, Department of Molecular Medicine, University of Padova). To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

FIG. 4. The central role of GPx4 in controlling iron-dependent lipid peroxidation. The initiating phospholipid carbon centered radical (PL[•]) of a polyunsaturated fatty acid of a membrane phospholipid (PL) is formed by: (a) an unspecified free radical (X[•]) (initiation); (b) a lipid hydroperoxyl radical (PLOO[•]) (propagation); and (c) a lipid alkoxyl radical (PLO[•]) (PLOOH-dependent initiation). Unstable PLOOH are produced by reduction of PLOO[•] by PL or α -tocopherol (α -TOH), and they are reduced into stable PLOH by GPx4 and GSH. Although other mechanisms are possible, the reported role of Fe²⁺ refers to the reductive cleavage of PLOOH yielding PLO[•]. Ferroptosis is seemingly executed by PLOOH and/or its decomposition products. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

and two-electron reactions—when PLOO[•] and PLOOH are reduced, respectively—accounts for the kinetic control of iron-dependent lipid peroxidation of membranes. Notably, an identical interplay between reactions quenching the propagation of hydroperoxyl radicals and “peroxidolytic reactions” (*i.e.*, reduction of hydroperoxides) is the core element for the kinetic control of reaction rate in polymer chemistry (97).

It is worth mentioning that the synergistic anti-peroxidant mechanism, including GPx4 and tocopherol, also applies to a peroxidation that is produced by lipoxygenase (LOX) activity (66). In fact: (i) PLOOH (or a hydroperoxide, in general) activates LOX (92), and thus membranes exposed to GPx4 and GSH are resistant to 12/15 LOX-dependent lipid peroxidation (96); and (ii) tocopherol inhibits LOX activity, seemingly by keeping the catalytic iron reduced (20). The observation that GPx4 silencing activates ferroptosis, and that this cell death subroutine is rescued by α -tocopherol (18, 72, 98, 115), validates the concept of the synergy between the two antioxidant mechanisms supporting the hypothesis of a functional node in the process of ferroptosis encompassing GPx4, GSH, tocopherol, oxygen, iron, and, likely, LOX activity (Fig. 5).

Cell and Animal Studies on the Role of GPx4 in Cell Death

Almost 20 years after the discovery of GPx4, studies using different cell lines indicated its primary role for protection

against oxidative damage (54, 116). These experiments, relying on GPx4 overexpression, provided the molecular explanation for the observation that selenium-supplemented cells, in selenium repletion studies, were more resistant than untreated cells to lipid hydroperoxide- and photooxidative-triggered cell death (42, 64). Successive studies finally pointed out to a specific role of GPx4 in preserving mitochondrial integrity (117).

Some sort of confusion about the potential role of different forms of GPx4 in cell death signaling came from overexpression studies suggesting that the mitochondrial form of GPx4 (mGPx4) rather than cytosolic GPx4 (cGPx4) was cytoprotective in response to cell stress challenges (3). mGPx4 distinguishes itself from cGPx4 by an N-terminal extension encoding a cognate mitochondrial targeting signal (4), which would confer localization to the mitochondrial matrix. mGPx4 overexpressing cells were also shown to be more resistant to 2-deoxyglucose-induced cell death by inhibiting cytochrome *c* release, nuclear fragmentation (78), adenine nucleotide translocator inactivation (53), and cardiolipin peroxidation (79), all of which are biochemical hallmarks of controlled cell death. Similar protective effects by mGPx4 were also observed in cells treated with pro-apoptotic cytotoxic compounds (78). However, in light of the specific expression patterns of the three different forms of GPx4 (86, 94), and follow-up studies using cells and mice with targeted loss of the entire *GPx4* gene or specific mouse mutants, these early studies must be taken with care as mGPx4 (like nuclear GPx4) is only essential during a specific step in sperm maturation and does not contribute to the essential pro-survival function of the cytosolic form of GPx4 in cell and tissue protection (63, 93, 98).

The targeted loss of the *GPx4* gene in mice eventually highlighted its outstanding importance for early development. Mice lacking GPx4 die, in fact, early in embryonic development, shortly after gastrulation (E7.5) (52, 125). Interestingly, the phenotype of the knockout of GPx4 resembles that of mice lacking the catalytic subunit of the enzyme catalyzing the first and rate-limiting step in GSH biosynthesis, γ -glutamyl-cysteine ligase (101). Moreover, knockout of the gene encoding the selenocysteine-specific tRNA (*Trsp*) also causes embryonic death at E6.5 (11), indicating that GPx4 is not only a limiting GSH-utilizing enzyme but also one of the most important selenoproteins.

Why nature selected selenium for some, although not all, peroxidases of vertebrates, evolving from a sulfur containing ancestor (106) has been recently unraveled. The reaction catalyzed by selenoperoxidases is faster (68), due to the better nucleophilic character of selenium in the oxidative part of the catalytic cycle and the better electrophilicity in the reductive part (90). This peculiar feature fits the result of the quantum-mechanical calculation of the energies of the transition states (81). Moreover, selenium, over sulfur, also offers the advantage of a better stability of the oxidized form of the enzyme. Here in fact, selenenic acid, when the reducing substrate is limited, reversibly forms a selenenylamide, whereas sulfur is irreversibly oxidized (81).

Due to the early embryonic lethal phenotype of homozygous *GPx4* null mice, a series of early studies regarding its cell-protective functions have been performed with heterozygous cells and mice, as no other conditional knockout tools for GPx4 were available at that time (39, 88, 125). In essence,

FIG. 5. Molecular players and inhibitors/inducers of ferroptosis. Cysteine availability either through uptake as cystine *via* the cystine/glutamate antiporter (System xc⁻) or from the trans-sulfuration pathway and GSH biosynthesis is one of the key upstream events in ferroptosis. Enrichment of membranes with long-chain ω -6 polyunsaturated fatty acids, such as AA and adrenic (AdA), preferably esterified in phosphatidylethanolamines (PE) mediated *via* acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) (31, 58), provides possible substrates for lipid hydroperoxides that are generated in an iron- and/or lipoxygenase (ALOX)-mediated manner. If not reduced by GPx4, PLOOH lead to the generation of yet-unidentified final ferroptotic death signals. Iron either taken up by transferrin receptor-mediated endocytosis or made available *via* ferritinophagy or heme oxygenase-1 (HO) may build up the so-called labile iron pool, which can contribute to lipid peroxidation. Inducers of ferroptosis are marked in red, and inhibitors are marked in green. γ -GCS, γ -glutamylcysteine synthetase; AA, arachidonic acid; BSO, L-buthionine sulfoximine; GS, glutathione synthetase; GSH, glutathione; GSSG, oxidized glutathione; TXNRD1, thioredoxin reductase 1. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

all these findings were in line with the previous over-expressing studies showing that cells and mice with only one functional *GPx4* allele are more sensitive to a number of stress-inducing agents and conditions such as hydroperoxides, γ -irradiation, and paraquat. Notably, mice with only one functional *GPx4* have decreased numbers of tumors and live somewhat longer than their wild-type counterparts (87). This suggests the hormetic effect of oxidants, where the loss of one *GPx4* allele leads to an associated increase in the steady-state level of lipid oxidation products, thereby activating a still unknown protective mechanism. Notwithstanding, these early investigations firmly established an essential function of GPx4 in the protection against PLOOH and related cytotoxic agents, while leaving the issue of the final mechanisms of cell death unresolved.

GPx4 as a Master Regulator of a Novel form of Regulated Necrotic Cell Death

A major leap in the molecular understanding of how GPx4 controls cell death (Fig. 5) was made by the introduction of the first conditional knockout mouse model in 2008 (98). This model additionally served as an ideal toolbox to generate a cellular system derived from mouse embryonic fibroblasts with two loxP-flanked *GPx4* alleles and stably expressing Tamoxifen-inducible Cre recombinase (now commonly referred to as "Pfa1 cells" (Fig. 6). Both conditional systems have been proved instrumental in unveiling the *in vivo* relevance of GPx4-dependent cell death and the underlying molecular mechanisms of this "yet-unrecognized cell-death pathway" (98). In this landmark study, not only could an

FIG. 6. Tamoxifen-inducible GPx4 knockout cells undergoing ferroptosis. Tamoxifen (TAM)-inducible GPx4 knockout cells ("Pfal cells") were treated with $1 \mu\text{M}$ 4-hydroxytamoxifen for 2 days to induce the knockout of GPx4, fixed, and analyzed by transmission electron microscopy, as described in Friedmann Angeli *et al.* (36). Unlike GPx4-proficient cells (-TAM), GPx4 knockout cells (+TAM) show swollen mitochondria and a progressive loss of cristae. In the upper right picture, a dying cell is presented (white arrow) next to a disintegrated dead cell (black arrow). Scale bars in the upper and lower panels are $2 \mu\text{m}$ and $0.5 \mu\text{m}$, respectively (The electron micrographs were kindly provided by Dr. Michaela Aichler, Helmholtz Zentrum München, Germany).

essential neuroprotective role for GPx4 in hippocampal neurons and in the prevention of ataxia and seizures of young mice be unmasked, but also first insights could be achieved in terms of the mechanism of cell death triggered on GPx4 inactivation. Moreover, with the increasing availability of conditional knockout models for GPx4 (Fig. 1), these critical observations could then be expanded to parvalbumin-positive interneurons (114), photoreceptor cells (107), cerebellar Purkinje cells and granular cells (113), as well as motor neurons (19) and forebrain neurons (46). And in fact, using second-generation ferroptosis inhibitors, it could be already shown that ferrostatins are neuroprotective in an *ex vivo* model for Huntington's disease (103), although *in vivo* proof is still lacking that ferroptosis inhibition, indeed, confers neuroprotection. In this context, it is noteworthy that depletion of cystathionine γ -lyase (CSE), a key enzyme of the trans-sulfuration pathway as an alternate cysteine source, was unveiled to possibly mediate Huntington's disease pathophysiology (84).

A specific tissue damage due to GPx4 silencing was also observed in skin (99) and the hematopoietic system (15). Notably, the morphological and functional alterations ob-

served in each tissue where GPx4 had been inactivated are practically overlapping those of spontaneous diseases. Thus, inactivation of the anti-peroxidant system based on GPx4 and the forthcoming ferroptotic death is seemingly the molecular mechanism of spontaneous diseases, against which therapeutic or preventive treatments could be specifically addressed.

The only caveat of the conditional knockout model is that it is impossible to specifically ablate just the cGPx4. Therefore, all three forms of GPx4 would always be concomitantly affected by the conditional knockout strategy of the entire *GPx4* gene. To this end, a major effort was undertaken and two additional knockout mouse models, one specific for the nuclear form and one for the mitochondrial one, were established. These investigations finally demonstrated that the nuclear and mitochondrial forms only confer specific functions during spermatogenesis but are otherwise dispensable in somatic tissues and for embryo development (24, 25, 51, 93). Unequivocal genetic proof that it is the cytosolic form being essential for embryogenesis and adult somatic tissues was eventually provided by an elegant study by Liang *et al.*, showing that transgenic expression of the cytosolic form in the *GPx4*^{-/-} background allowed normal development and full viability of mice (63). Most interestingly, subcellular fractionations of cells and mitochondria from *cGPx4*-*GPx4*^{-/-} transgenic liver and kidneys revealed that cytosolic GPx4 appears to be highly enriched in the intermembrane space of mitochondria (IMS) and absent in the mitochondrial matrix, suggesting a crucial role for the peroxidase in this particular subcellular location. Notably, an early study based on biochemical evidence of sub-cellular localization suggested that, in rat brain mitochondria, GPx4 is located in the inner mitochondrial membrane and contact sites (82). Together, these studies suggest that the GPx4 site of action is the outer face of the mitochondrial inner membrane. The mechanism of how "cytosolic" GPx4 enters the IMS, however, remains unknown, but it appears to be shared with other professional redox enzymes that are usually located in the cytosol, such as GPx1, SOD1, and thioredoxin reductase 1 (TXNRD1).

Remarkably, cell death triggered by the inducible deletion of *GPx4* in Pfal cells as well as *ex vivo* cultured cortical neurons from E15.5 embryos could be fully prevented by α -tocopherol (98), which was later demonstrated to be of utmost relevance for the *in vivo* situation. For instance, sufficient α -tocopherol content in the mouse chow or supra-nutritional α -tocopherol supplementation was demonstrated to compensate for the loss of GPx4 in endothelial cells (115), CD8⁺ T cells (72), and hepatocytes of newborn pups (18). Preliminary studies with the cellular Pfal system suggested the involvement of apoptosis-inducing factor (AIF; a misacronym for the involvement in "apoptosis") and LOX-derived lipid hydroperoxides (in particularly that of 12/15-lipoxygenase) in the cell death mechanisms downstream of *GPx4* deletion (98). However, these findings were largely based on inhibitor and cellular studies, with all the known caveats of possible unspecific side effects (*e.g.*, radical trapping antioxidant activity).

In 2012, Stockwell's group introduced the term "ferroptosis," a novel form of cell death induced by a class of compounds able to selectively kill tumor cells expressing an oncogenic RAS. Based on morphological, biochemical, and

genetic traits, this new cell death modality emerged to be entirely different from apoptosis, necroptosis, autophagic cell death, and other forms of regulated necrotic cell death (29). The cell death induced by ferroptosis-inducing agents is characterized by an iron-dependent lipid peroxidation event detected as oxidation of C11-BODIPY (33), a probe reacting with free radicals produced during membrane peroxidation. Consistent with the involvement of lipid peroxidation, ferroptosis is inhibited by iron chelators and α -tocopherol. Ferrostatin-1 was also identified as a potent inhibitor of ferroptosis for which a free radical scavenging mechanism had been proposed (103).

As mentioned earlier, ferroptosis inhibitors were shown to be particularly effective in preventing cell death in organotypic brain slices exposed to a high concentration of glutamate. This is reminiscent of a previously described form of cell death, called oxytosis (104), which can be induced by millimolar concentrations of extracellular glutamate in neuronal and non-neuronal cells. A high extracellular concentration of glutamate blocks the cystine-glutamate antiporter, system x_c^- , thus leading to impaired cystine uptake and, consequently, impaired GSH biosynthesis.

In agreement with the mechanism described earlier, ferroptosis is also triggered in sensitive cells by the small molecule erastin (32), first described to interact with voltage-dependent anion channels (118), and then shown to inhibit system x_c^- (29). Two years later, in search of the target for (1S, 3R)-RSL3 (RSL3), a compound previously shown to induce ferroptosis without depleting the GSH pool, the same group identified GPx4 as the target that was efficiently inhibited in cells by this compound (121). RSL3-induced cancer cell death was feasible in a BJeLR xenograft cancer model and appeared to be highly effective in tumor cell lines of large B cell lymphoma and of renal cell carcinoma origins. However, whether GPx4 is really a valid target to efficiently eradicate tumor cells *in vivo* needs to be further explored, particularly in light of earlier data, which pointed to a dispensable role of GPx4 in cell survival and proliferation in a syngeneic tumor transplantation model of *c-Myc/H-ras^{V12}*-transformed GPx4-deficient fibroblasts (95). This dispensability of GPx4 is in line with earlier findings, where it was shown that GPx4 knockout cells are, indeed, able to proliferate under normal cell culture conditions when seeded at higher cell densities (98), or when grown as single cells in Matrigel (95). The evidence is consistent with the notion that oxygen tension and activation could become the rate-limiting determinant of oxidative reactions, eventually leading to cell death. A recent intriguing observation, in agreement with a major role of oxygen in cell death, is the apparent paradox of a protective effect of hypoxia in heart regeneration (76). Furthermore, the notion that ferroptosis is activated during neuronal reprogramming further contributes toward pointing out the relevance of lipid peroxidation in the control of efficiency of cellular reprogramming and proliferation (41).

In 2014, a first evidence that ferroptosis is relevant not only for cancer cell death but also in renal tubule cell death and in a mouse model of hepatic ischemia/reperfusion injury *in vivo* was provided (36). The tamoxifen-inducible deletion of GPx4 in adult mice was shown to cause acute renal failure and early death of mice, which could be delayed by liproxstatin-1, the first *in vivo* efficacious ferroptosis inhibitor. Liproxstatin-1 also proved to mitigate the damage in-

flicted by transient ischemia/reperfusion in the liver in wild-type mice while also firmly increasing neuronal reprogramming during fate conversion of astrocytes to functional neurons (40). Moreover, it was found that GPx4 inactivation-induced cell death presents as a major morphological alteration in the rupture of the outer mitochondrial membrane, which is accompanied by alterations in the oxi-lipidomic signature in cells and in knockout tissues; all the changes could be suppressed by ferrostatin-1, necrostatin-1 (an apparent off-target effect independently of its action toward receptor-interacting serine/threonine-protein kinase 1 [Ripk1]), and various lipoxygenase inhibitors (36). Thus, the observed morphological mitochondrial changes may well fit with the preferential localization of cGPx4 to the IMS and/or inner membrane outer surface (63, 82).

Most recently, another downstream ferroptosis player, acyl-CoA synthetase long-chain family member 4 (ACSL4), was unraveled and functionally characterized in the ferroptotic process (31, 58) (Fig. 5). Knockout of ACSL4 in Pfa1 cells or breast cancer cells as well as neuronal cells provided an unprecedented protection against ferroptosis induced by genetic *GPx4* deletion or GPx4 inhibition (31). The same protective effect could be achieved when cells were treated with thiazolidinediones, an antidiabetic class of compounds that, as a side effect, also inhibit ACSL4 over other ACSL isoforms (60). The underlying mechanism of this robust anti-ferroptotic effect conferred by ACSL4 knockout or pharmacological inhibition was shown to rely on a strongly reduced incorporation of long ω -6 polyunsaturated fatty acids, such as arachidonic and adrenic acid, into a seemingly specific class of phospholipids (mainly phosphatidylethanolamine), thus dramatically lowering the susceptibility to lipid peroxidation events in membranes (31, 58). Hence, pharmacological targeting of ACSL4 in some degenerative disease contexts, such as neurodegeneration or ischemia/reperfusion scenarios, could provide beneficial effects. In addition, an alternative route for ferroptosis engagement was recently identified. The small molecule FIN56 leads to degradation of GPx4 through a not-fully understood mechanism that may involve activation of ACC1 (acetyl-CoA carboxylase), an enzyme involved in fatty acid synthesis (102).

In terms of the ferroptotic process *per se*, a number of reports published during the past few years have provided further upstream mechanistic details about the involvement of iron handling, p53-dependent regulation of SLC7A11 (the substrate-specific subunit of system x_c^-), and availability of cysteine *via* the trans-sulfuration pathway, which have been extensively illuminated in a recent comprehensive review article (16).

Major Open Issues and Future Directions

How is the “first” hydroperoxide formed?

The inhibition of iron-dependent lipid peroxidation by GPx4 and GSH points out the relevance of PLOOH but leaves open the question about the formation of the traces of PLOOH from which, in the absence of GPx4 activity, ferrous iron sparks lipid peroxidation.

Possible candidates for the formation of an initial PL $\bullet$ (Fig. 4), evolving into PLOO $\bullet$ and then PLOOH, are free radicals that are produced in living cells, such as the protonated superoxide anion (1) or the perferryl iron-oxygen

complex (109) or the hydroxyl radical (126). The efficiency of these reactions in initiating lipid peroxidation, however, is extremely low in comparison to that of PLOOH-dependent initiation (105). No iron-dependent lipid peroxidation is, indeed, detectable when GSH and GPx4 are present, and traces of PLOOH formed are continuously reduced. Consistently, it seems reasonable to assume that traces of hydroxyl derivatives of membrane lipids (PLOH) are continuously produced and could be physiologically relevant, for instance, in controlling membrane lipid turnover.

Source of iron

Iron is indispensable for lipid peroxidation; however, although the name “ferroptosis” remarks this fact, very little is known about the form of cellular iron involved, besides the fact that chelation with desferoxamine prevents both lipid peroxidation and cell death (109, 122). The recent indication that the activity of the catalytic subunit of phosphorylase kinase (120) releases iron, although intriguing, does not contribute toward solving the issue. Typically, iron is released from ferritin by controlled proteasomal degradation (5), known as ferritinophagy, and participates in the heterogeneous “labile iron pool” (LIP) consisting of low-molecular-weight complexes from which iron enters into different metabolic pathways (100).

LIP can have a role in the activation of membrane peroxidation in two respects: by forming perferryl or hydroxyl species that are able to extract a hydrogen atom from a methylene carbon of a polyunsaturated fatty acid in PL and, much more efficiently, by participating in an organic Fenton reaction with a PLOOH (105, 109) (Fig. 4). In either case, oxygen concentration and the redox potential, type of coordination, and reducibility of the iron complex are the determinants of the actual pro-peroxidative effect. The relevance of the redox status of iron complexes is unquestionable in microsomal lipid peroxidation *in vitro*, where a continuous supply of electrons to the iron complex is indispensable. A pathophysiological evidence indirectly supporting the relevance of the redox status *in vivo* is the neurodegeneration associated to aceruloplasminemia, where lipid peroxidation is sparked by iron accumulating in the brain in the ferrous form due to absent ferroxidase activity of ceruloplasmin (73). Also the evidence that heme-oxygenase 1, which releases reduced iron, accelerates erastin-induced ferroptotic cell death (61) further confirms the relevance of iron concentration and sheds some light on a possible pro-ferroptotic effect of Nrf2 activation, which primes heme-oxygenase 1 expression.

Decrease of GSH

The decrease of GSH produced by erastin, which replenishes cells of cysteine for GSH biosynthesis (*via* cystine) (124), is the first mechanism of induction of ferroptosis identified in oncogenic RAS mutant cell lines. Consistently, GSH depletion by alkylation or inhibition of synthesis activates ferroptosis (65, 123). Thus, the question emerges about the nature of the physiological or pathological events leading to GSH depletion. One well-defined mechanism is related to the toxicity of glutamate competing for cystine uptake (59). However, other mechanisms have been described, such as the inhibition of the system x_c^- (56), GSH depletion by active

efflux (35), or inhibition of CSE (84). In this respect, it is intriguing recalling that in the late phase of spermatogenesis GSH is almost completely depleted but this does not prime cell death but, instead, the moonlighting of GPx4, which becomes a cross-linked structural component of the mitochondrial capsule (108). Unraveling the analogies between two so different biological events will most likely shed some light on this unexpected similarity between cell death and sperm maturation.

Inhibition of GPx4

The clear-cut evidence that GPx4 silencing almost invariably causes ferroptosis stimulates the still unresolved question about a downregulation of the enzyme under specific physiological or pathological conditions, which might involve a post-translational modification and/or the activation of a proteolytic degradation. The inhibition of GPx4 in cells by the drug candidate RSL3 suggests the alkylation of the catalytic selenol as a suitable mechanism of irreversible inhibition of the peroxidase. Although such a mechanism frames the inhibition of GPx4 in the area of cancer pharmacology, it would be interesting knowing whether endogenously produced electrophiles could produce a similar effect.

Role of lipoxygenases

Despite the alleged role for one or more lipoxygenases in the cell death process downstream of GPx4 deletion/inactivation (36, 98), robust genetic proof that GPx4/lipoxygenase double knockout mutant are, in fact, protected against the lethality brought about by GPx4 deficiency is still lacking. Knockout of *Alox15* (the gene encoding 12/15-lipoxygenase) in the *GPx4*^{-/-} background, indeed, failed to rescue from early embryonic lethality (12), nor did it rescue acute renal failure and early death of adult tamoxifen-inducible GPx4 knockout mice (36). Hence, data showing an anti-ferroptotic effect by either deleting a distinctive lipoxygenase (*i.e.*, 15-LOX) (98) or knocking down one or several LOX isoforms (120) are currently restricted to the cellular level and need validation in an *in vivo* relevant setting.

Although lipoxygenases are typically described as enzymes that are active on free fatty acids, in support of the activity on membrane lipids already observed for soybean LOX-2 (67) stands the recent evidence of the activity of 15-LOX-2 on membrane PL (9), the formation of eicosanoids of intact PL (21, 47, 74), and physiological function of the reticulocyte LOX (89). This enzyme is, indeed, competent by forming PLOOH for the destruction of mitochondria in the late phase of red blood cell maturation. Remarkably, it has been shown that this LOX active on phospholipid of sub-mitochondrial particles is fully inhibited by GPx4 (96). Moreover, in the presence of an appropriate GPx4 activity, the reticulocyte LOX produces stereo-specific PLOH. This suggests a possible specific function for these species, such as in membrane turnover and autophagy, as recently observed (75). In the area of neuroinflammation and neurodegeneration, the role of 5-LOX (57) and 12/15 LOX (85) has been convincingly demonstrated. Finally, the notion that LOX can be active on intact phospholipids raises the relevant question about the mechanism of the reaction. In fact, although it has been demonstrated that LOX can bind to bilayers (55), what is still unclear is how fatty acid chains esterified in PL could

emerge from membrane and reach the catalytic center of the enzyme.

Role of α -tocopherol

The inhibition of ferroptosis by α -tocopherol (6, 98, 123) in the absence of GPx4 is still far from being clearly understood. In chemical terms, reduction of PLOO $\cdot$ by α -tocopherol cannot substitute for reduction of PLOOH. At least *in vitro* the two reactions are, instead, complementary in the concerted antioxidant mechanism (Fig. 4), where PLOOH, produced by one-electron transfer from PLOO $\cdot$, are reduced by GPx4. An option, which can explain the data coming from animals or cells, is the inhibition of lipoxygenases (20). This effect, indeed, could give an account for the observed inhibition of ferroptosis. Moreover, this hypothesis would suggest the notion that ferroptosis can only take place after a consumption of α -tocopherol, which is expected to be oxidized while keeping reduced the catalytic iron of LOX. This could frame a new, interesting, role for the vitamin as controller that delays the programmed cell death execution. However, unfortunately, specifically addressed analytical evidence that could clarify this relevant issue is still missing.

Which are the species actually killing cells and which are the final events leading to cell death?

Granted the central role of PLOOH in the mechanism of ferroptosis, what is completely obscure is the series of final events. Are PLOOH the final agonists, possibly operating a redox transition on a target? Or are they the precursors of other species specifically committed for this function? Truncated cardiolipin is a possible reasonable candidate for this function, and, in fact, it had been reported to be involved in mitochondrial apoptosis (62), although this is, indeed, a form of cell death that is different from ferroptosis. Specific decomposition products of PLOOH containing ω -6 fatty acids may have a role, and, consistently, ACSL4, which enriches cellular membranes with ω -6 fatty acids, has been recently found as an essential component for ferroptosis execution (31). Remarkably, ω -6 fatty acid decomposition produces 4-hydroxynonenal (HNE) (27, 126) and the AKR1C1-3 (aldo-keto reductase family 1 members C1-3) enzymes, which participate in the detoxification of alkenals (such as HNE), were found to be overexpressed in cells resistant to ferroptosis induced by erastin (30). However, although HNE has been shown to be competent for activation of a cell death pathway (27), the proof that it is the actual executor of ferroptosis is missing. At the present level of knowledge, we could just assume as likely the hypothesis that electrophiles produced by decomposition of PLOOH in membranes could participate in redox reactions of the death signaling pathway.

Conclusions

Iron-dependent lipid peroxidation, discovered several decades ago as an oxidative process where traces of iron and a source of reducing equivalents destroy microsomal membranes, has been rediscovered today as a specific form of cell death. The present set of evidences, indeed, revisits the biochemical events of lipid peroxidation in the frame of a controlled process of major biological relevance. The players of

the pro- and anti-peroxidant mechanism are oxygen, membrane phospholipids, ferrous iron, GSH, GPx4, α -tocopherol, and, possibly, lipoxygenase(s). Available evidence indicates that it is the decrease of the efficiency of the anti-peroxidant mechanism that primes the formation of molecules—seemingly oxidized derivatives of membrane lipids—executing the death sentence. What we still do not know is the chemical nature of these species and the specific elements accounting for the variable sensitivity of different cells to ferroptosis, among which membrane composition and structural constraints are expected to play a relevant role. In addition, although the role of ferroptosis in cell death has been well documented in pathological conditions, it has been also suggested that the control by p53 of GSH level and thus of ferroptotic cell death participates in tissue plasticity (56), even though xCT (the gene product of *SLC7A11*) is dispensable for life in mice (91). In this light, what emerges today is that cell death by lipid peroxidation is not only confined to toxicology, but it is, indeed, a critical element of the balance between cell proliferation and death. This impacts life from embryogenesis to tissue homeostasis, likely affecting cellular reprogramming, as recently observed in the elegant study by Gascón *et al.*, showing that inhibition of lipid peroxidation greatly enhances the efficiency of the conversion of astrocytes to functional neurons (41).

Acknowledgments

This study was supported by the Human Frontier Science Program, Grant RGP0013/2014 to F.U. and M.C. and Deutsche Forschungsgemeinschaft CO 291/2-3; CO 291/5-1 to M.C.

References

1. Aikens J and Dix TA. Peroxy radical (HOO $\cdot$) initiated lipid peroxidation. The role of fatty acid hydroperoxides. *J Biol Chem* 266: 15091–15098, 1991.
2. Antunes F, Salvador A, Marinho HS, Alves R, and Pinto RE. Lipid peroxidation in mitochondrial inner membranes. I. An integrative kinetic model. *Free Radic Biol Med* 21: 917–943, 1996.
3. Arai M, Imai H, Koumura T, Yoshida M, Emoto K, Umeda M, Chiba N, and Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells. *J Biol Chem* 274: 4924–4933, 1999.
4. Arai M, Imai H, Sumi D, Imanaka T, Takano T, Chiba N, and Nakagawa Y. Import into mitochondria of phospholipid hydroperoxide glutathione peroxidase requires a leader sequence. *Biochem Biophys Res Commun* 227: 433–439, 1996.
5. Arosio P and Levi S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. *Biochim Biophys Acta* 1800: 783–792, 2010.
6. Back SA, Gan X, Li Y, Rosenberg PA, and Volpe JJ. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. *J Neurosci* 18: 6241–6253, 1998.
7. Barclay L and Ingold KU. Autoxidation of biological molecule. 2. The autoxidation of a model membrane: a comparison of the autoxidation of egg lecithin phosphatidyl choline in water and in chlorobenzene. *J Am Chem Soc* 103: 6478–6485, 1981.

8. Bellinger FP, Bellinger MT, Seale LA, Takemoto AS, Raman AV, Miki T, Manning-Boğ AB, Berry MJ, White LR, and Ross GW. Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain. *Mol Neurodegener* 6: 8, 2011.
9. Bender G, Schexnaydre EE, Murphy RC, Uhlson C, and Newcomer ME. Membrane-dependent activities of human 15-LOX-2 and its murine counterpart: implications for murine models of atherosclerosis. *J Biol Chem* 291: 19413–19424, 2016.
10. Bosello-Travain V, Conrad M, Cozza G, Negro A, Quartesan S, Rossetto M, Roveri A, Toppo S, Ursini F, Zaccarin M, and Maiorino M. Protein disulfide isomerase and glutathione are alternative substrates in the one Cys catalytic cycle of glutathione peroxidase 7. *Biochim Biophys Acta* 1830: 3846–3857, 2013.
11. Bosl MR, Takaku K, Oshima M, Nishimura S, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). *Proc Natl Acad Sci U S A* 94: 5531–5534, 1997.
12. Brutsch SH, Wang CC, Li L, Stender H, Neziroglu N, Richter C, Kuhn H, and Borchert A. Expression of inactive glutathione peroxidase 4 leads to embryonic lethality, and inactivation of the alox15 gene does not rescue such knock-in mice. *Antioxid Redox Signal* 22: 281–293, 2015.
13. Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, α -tocopherol, and ascorbate. *Arch Biochem Biophys* 300: 535–543, 1993.
14. Burton GW and Ingold KU. Autoxidation of biological molecules. 1. Antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro. *J Am Chem Soc* 103: 6472–6477, 1981.
15. Canli Ö, Alankuş YB, Grootjans S, Vegi N, Hültner L, Hoppe PS, Schroeder T, Vandenabeele P, Bornkamm GW, and Greten FR. Glutathione peroxidase 4 prevents necroptosis in mouse erythroid precursors. *Blood* 127: 139–148, 2015.
16. Cao JY and Dixon SJ. Mechanisms of ferroptosis. *Cell Mol Life Sci* 73: 2195–2209, 2016.
17. Cardoso BR, Hare DJ, Bush AI, and Roberts BR. Glutathione peroxidase 4: a new player in neurodegeneration? *Mol Psychiatry* 22: 328–335, 2017.
18. Carlson BA, Tobe R, Yefremova E, Tsuji PA, Hoffmann VJ, Schweizer U, Gladyshev VN, Hatfield DL, and Conrad M. Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration. *Redox Biol* 9: 22–31, 2016.
19. Chen L, Hambright WS, Na R, and Ran Q. Ablation of ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. *J Biol Chem* 290: 28097–28106, 2015.
20. Cichewicz RH, Kenyon VA, Whitman S, Morales NM, Arguello JF, Holman TR, and Crews P. Redox inactivation of human 15-lipoxygenase by marine-derived meroditerpenes and synthetic chromanes: archetypes for a unique class of selective and recyclable inhibitors. *J Am Chem Soc* 126: 14910–14920, 2004.
21. Clark SR, Guy CJ, Scurr MJ, Taylor PR, Kift-Morgan AP, Hammond VJ, Thomas CP, Coles B, Roberts GW, Eberl M, Jones SA, Topley N, Kotecha S, and O'Donnell VB. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. *Blood* 117: 2033–2043, 2011.
22. Cong W-n, Cai H, Wang R, Daimon CM, Maudsley S, Raber K, Canneva F, von Hörsten S, and Martin B. Altered hypothalamic protein expression in a rat model of Huntington's disease. *PLoS ONE* 7: e47240, 2012.
23. Conrad M, Angeli JPF, Vandenabeele P, and Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. *Nat Rev Drug Discov* 15: 348–366, 2016.
24. Conrad M, Ingold I, Buday K, Kobayashi S, and Angeli JP. ROS, thiols and thiol-regulating systems in male gametogenesis. *Biochim Biophys Acta* 1850: 1566–1574, 2015.
25. Conrad M, Moreno SG, Sinowatz F, Ursini F, Kolle S, Roveri A, Brielmeier M, Wurst W, Maiorino M, and Bornkamm GW. The nuclear form of phospholipid hydroperoxide glutathione peroxidase is a protein thiol peroxidase contributing to sperm chromatin stability. *Mol Cell Biol* 25: 7637–7644, 2005.
26. Crotti A and Glass CK. The choreography of neuroinflammation in Huntington's disease. *Trends Immunol* 36: 364–373, 2015.
27. Dalleau S, Baradat M, raud FGe, and Huc L. Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. *Cell Death Differ* 20: 1615–1630, 2013.
28. De Saussure N. *Recherches Chimiques sur la Végétation*. Paris: Nyon librairie, 1804, p. 327.
29. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, 3rd, and Stockwell BR. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* 149: 1060–1072, 2012.
30. Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, and Stockwell BR. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *Elife* 3: e02523, 2014.
31. Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmeler M, Beckers J, Aichler M, Walch A, Prokisch H, Trümbach D, Mao G, Qu F, Bayir H, Füllkrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JPF, and Conrad M. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. *Nat Chem Biol* 13: 91–98, 2017.
32. Dolma S, Lessnick SL, Hahn WC, and Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. *Cancer Cell* 3: 285–296, 2003.
33. Drummen GPC, Gadella BM, Post JA, and Brouwers JF. Mass spectrometric characterization of the oxidation of the fluorescent lipid peroxidation reporter molecule C11-BODIPY(581/591). *Free Radic Biol Med* 36: 1635–1644, 2004.
34. Fisher AB, Dodia C, Manevich Y, Chen JW, and Feinstein SI. Phospholipid hydroperoxides are substrates for non-selenium glutathione peroxidase. *J Biol Chem* 274: 21326–21334, 1999.
35. Franco R and Cidlowski JA. Glutathione efflux and cell death. *Antioxid Redox Signal* 17: 1694–1713, 2012.
36. Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, Basavarajappa D, Radmark O, Kobayashi S, Seibt T, Beck H, Neff F, Esposito I, Wanke R, Forster H, Yefremova O, Heinrichmeyer M, Bornkamm GW, Geissler EK, Thomas SB, Stockwell BR,

- O'Donnell VB, Kagan VE, Schick JA, and Conrad M. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. *Nat Cell Biol* 16: 1180–1191, 2014.
37. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin K-M, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon M-L, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine J-C, Martin SJ, Martinou J-C, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon H-U, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, and Kroemer G. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death Differ* 22: 58–73, 2014.
 38. Garrec J, Monari A, Assfeld X, Mir LM, and Tarek M. Lipid peroxidation in membranes: the peroxy radical does not “float.” *J Phys Chem Lett* 5: 1653–1658, 2014.
 39. Garry MR, Kavanagh TJ, Faustman EM, Sidhu JS, Liao R, Ware C, Vliet PA, and Deeb SS. Sensitivity of mouse lung fibroblasts heterozygous for GPx4 to oxidative stress. *Free Radic Biol Med* 44: 1075–1087, 2008.
 40. Gascon S, Murenu E, Masserdotti G, Ortega F, Russo GL, Petrik D, Deshpande A, Heinrich C, Karow M, Robertson SP, Schroeder T, Beckers J, Irmeler M, Berndt C, Angeli JP, Conrad M, Berninger B, and Gotz M. Identification and successful negotiation of a metabolic checkpoint in direct neuronal reprogramming. *Cell Stem Cell* 18: 396–409, 2016.
 41. Gascón S, Murenu E, Masserdotti G, Ortega F, Russo GL, Petrik D, Deshpande A, Heinrich C, Karow M, Robertson SP, Schroeder T, Beckers J, Irmeler M, Berndt C, Angeli JPF, Conrad M, Berninger B, and Götz M. Identification and successful negotiation of a metabolic checkpoint in direct neuronal reprogramming. *Cell Stem Cell* 18: 396–409, 2016.
 42. Geiger PG, Thomas JP, and Girotti AW. Lethal damage to murine L1210 cells by exogenous lipid hydroperoxides: protective role of glutathione-dependent selenoperoxidases. *Arch Biochem Biophys* 288: 671–680, 1991.
 43. Gibson DD, Hornbrook KR, and McCay PB. Glutathione-dependent inhibition of lipid peroxidation by a soluble, heat-labile factor in animal tissues. *Biochim Biophys Acta* 620: 572–582, 1980.
 44. Gladyshev VN, Arner ES, Berry MJ, Brigelius-Flohé R, Bruford EA, Burk RF, Carlson BA, Castellano S, Chavatte L, Conrad M, Copeland PR, Diamond AM, Driscoll DM, Ferreiro A, Flohé L, Green FR, Guigo R, Handy DE, Hatfield DL, Hesketh J, Hoffmann PR, Holmgren A, Hondal RJ, Howard MT, Huang K, Kim HY, Kim IY, Kohrle J, Krol A, Kryukov GV, Lee BJ, Lee BC, Lei XG, Liu Q, Lescure A, Lobanov AV, Loscalzo J, Maiorino M, Mariotti M, Prabhu KS, Rayman MP, Rozovsky S, Salinas G, Schmidt EE, Schomburg L, Schweizer U, Simonovic M, Sunde RA, Tsuji PA, Tweedie S, Ursini F, Whanger PD, and Zhang Y. Selenoprotein Gene Nomenclature. *J Biol Chem* 291: 24036–24040, 2016.
 45. Guiney SJ, Adlard PA, Bush AI, Finkelstein DI, and Aytton S. Ferroptosis and cell death mechanisms in Parkinson's disease. *Neurochem Int* 104: 34–48, 2017.
 46. Hambright WS, Fonseca RS, Chen L, Na R, and Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. *Redox Biol* 12: 8–17, 2017.
 47. Hammond VJ and O'Donnell VB. Esterified eicosanoids: generation, characterization and function. *Biochim Biophys Acta* 1818: 2403–2412, 2012.
 48. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschi SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, and Kummer MP. Neuroinflammation in Alzheimer's disease. *Lancet Neurol* 14: 388–405, 2015.
 49. Hirsch EC, Vyas S, and Hunot S. Neuroinflammation in Parkinson's disease. *Parkinsonism Relat Disord* 18: S210–S212, 2011.
 50. Hochstein P and Ernster L. ADP-activated lipid peroxidation coupled to the TPNH oxidase system of microsomes. *Biochem Biophys Res Commun* 12: 388–394, 1963.
 51. Imai H, Hakkaku N, Iwamoto R, Suzuki J, Suzuki T, Tajima Y, Konishi K, Minami S, Ichinose S, Ishizaka K, Shioda S, Arata S, Nishimura M, Naito S, and Nakagawa Y. Depletion of selenoprotein GPx4 in spermatocytes causes male infertility in mice. *J Biol Chem* 284: 32522–32532, 2009.
 52. Imai H, Hirao F, Sakamoto T, Sekine K, Mizukura Y, Saito M, Kitamoto T, Hayasaka M, Hanaoka K, and Nakagawa Y. Early embryonic lethality caused by targeted disruption of the mouse PHGPx gene. *Biochem Biophys Res Commun* 305: 278–286, 2003.
 53. Imai H, Koumura T, Nakajima R, Nomura K, and Nakagawa Y. Protection from inactivation of the adenine nucleotide translocator during hypoglycaemia-induced apoptosis by mitochondrial phospholipid hydroperoxide glutathione peroxidase. *Biochem J* 371: 799–809, 2003.
 54. Imai H, Sumi D, Sakamoto H, Hanamoto A, Arai M, Chiba N, and Nakagawa Y. Overexpression of phospholipid hydroperoxide glutathione peroxidase suppressed cell death due to oxidative damage in rat basophilic leukemia cells (RBL-2H3). *Biochem Biophys Res Commun* 222: 432–438, 1996.
 55. Järving R, Lööken A, Kurg R, Siimon L, Järving I, and Samel N. Activation of 11R-lipoxygenase is fully Ca(2+)-dependent and controlled by the phospholipid composition of the target membrane. *Biochemistry* 51: 3310–3320, 2012.

56. Jiang L, Kon N, Li T, Wang S-J, Su T, Hibshoosh H, Baer R, and Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. *Nature* 520: 57–62, 2015.
57. Joshi YB and Praticò D. The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. *Front Cell Neurosci* 8: 436, 2014.
58. Kagan VE, Mao G, Qu F, Angeli JPF, Doll S, Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, Kapralov AA, Amoscato AA, Jiang J, Anthonymuthu T, Mohammadyani D, Yang Q, Proneth B, Klein-Seetharaman J, Watkins S, Bahar I, Greenberger J, Mallampalli RK, Stockwell BR, Tyurina YY, Conrad M, and Bayir H. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. *Nat Chem Biol* 13: 81–90, 2017.
59. Kato S, Negishi K, Mawatari K, and Kuo CH. A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion. *Neuroscience* 48: 903–914, 1992.
60. Kim JH, Lewin TM, and Coleman RA. Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. *J Biol Chem* 276: 24667–24673, 2001.
61. Kwon M-Y, Park E, Lee S-J, and Chung SW. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. *Oncotarget* 6: 24393–24403, 2015.
62. Latchoumycandane C, Marathe GK, Zhang R, and McIntyre TM. Oxidatively truncated phospholipids are required agents of TNF α induced apoptosis. *J Biol Chem* 287: 17693–17705, 2012.
63. Liang H, Yoo SE, Na R, Walter CA, Richardson A, and Ran Q. Short form glutathione peroxidase 4 is the essential isoform required for survival and somatic mitochondrial functions. *J Biol Chem* 284: 30836–30844, 2009.
64. Lin F, Geiger PG, and Girotti AW. Selenoperoxidase-mediated cytoprotection against merocyanine 540-sensitized photoperoxidation and photokilling of leukemia cells. *Cancer Res* 52: 5282–5290, 1992.
65. Lőrincz T, Jemnitz K, Kardon T, Mandl J, and Szarka A. Ferroptosis is Involved in Acetaminophen Induced Cell Death. *Pathol Oncol Res* 21: 1115–1121, 2015.
66. Maccarrone M, Melino G, and Finazzi-Agrò A. Lipoxigenases and their involvement in programmed cell death. *Cell Death Differ* 8: 776–784, 2001.
67. Maccarrone M, van Aarle P, Veldink G, and Vliegenthart JF. In vitro oxygenation of soybean biomembranes by lipoxygenase-2. *Biochim Biophys Acta* 1190: 164–169, 1994.
68. Maiorino M, Aumann KD, Brigelius-Flohé R, Doria D, van den Heuvel J, McCarthy J, Roveri A, Ursini F, and Flohé L. Probing the presumed catalytic triad of selenium-containing peroxidases by mutational analysis of phospholipid hydroperoxide glutathione peroxidase (PHGPx). *Biol Chem Hoppe-Seyler* 376: 651–660, 1995.
69. Maiorino M, Bosello-Travain V, Cozza G, Miotto G, Orian L, Roveri A, Toppo S, Zaccarin M, and Ursini F. Glutathione peroxidase 4. In: *Selenium: Its Molecular Biology and Role in Human Health*, edited by Hatfield DL, Schweizer U, Tsuji PA and VN G. New York, NY: Springer, 2016, pp. 223–234.
70. Maiorino M, Coassin M, Roveri A, and Ursini F. Microsomal lipid peroxidation: effect of vitamin E and its functional interaction with phospholipid hydroperoxide glutathione peroxidase. *Lipids* 24: 721–726, 1989.
71. Maiorino M, Gregolin C, and Ursini F. Phospholipid hydroperoxide glutathione peroxidase. *Meth Enzymol* 186: 448–457, 1990.
72. Matsushita M, Freigang S, Schneider C, Conrad M, Bornkamm GW, and Kopf M. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. *J Exp Med* 212: 555–568, 2015.
73. Miyajima H. Aceruloplasminemia. *Neuropathology* 35: 83–90, 2015.
74. Morgan AH, Dioszeghy V, Maskrey BH, Thomas CP, Clark SR, Mathie SA, Lloyd CM, Kuhn H, Topley N, Coles BC, Taylor PR, Jones SA, and O'Donnell VB. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. *J Biol Chem* 284: 21185–21191, 2009.
75. Morgan AH, Hammond VJ, Sakoh-Nakatogawa M, Ohsumi Y, Thomas CP, Blanchet F, Piguet V, Kiselyov K, and O'Donnell VB. A novel role for 12/15-lipoxygenase in regulating autophagy. *Redox Biol* 4: 40–47, 2015.
76. Nakada Y, Canseco DC, Thet S, Abdulsalam S, Asaithamby A, Santos CX, Shah A, Zhang H, Faber JE, Kinter MT, Szweda LI, Xing C, Deberardinis R, Oz O, Lu Z, Zhang CC, Kimura W, and Sadek HA. Hypoxia induces heart regeneration in adult mice. *Nature* 541: 222–227, 2017.
77. Neta P, Grodkowski J, and Ross AB. Rate constants for reactions of aliphatic carbon-centered radicals in aqueous solution. *J Phys Chem Ref Data* 25: 709–1050, 1996.
78. Nomura K, Imai H, Koumura T, Arai M, and Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase suppresses apoptosis mediated by a mitochondrial death pathway. *J Biol Chem* 274: 29294–29302, 1999.
79. Nomura K, Imai H, Koumura T, Kobayashi T, and Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis. *Biochem J* 351: 183–193, 2000.
80. Olson GE, Whitin JC, Hill KE, Winfrey VP, Motley AK, Austin LM, Deal J, Cohen HJ, and Burk RF. Extracellular glutathione peroxidase (Gpx3) binds specifically to basement membranes of mouse renal cortex tubule cells. *Am J Physiol Renal Physiol* 298: F1244–F1253, 2010.
81. Orian L, Mauri P, Roveri A, Toppo S, Benazzi L, Bosello-Travain V, De Palma A, Maiorino M, Miotto G, Zaccarin M, Polimeno A, Flohé L, and Ursini F. Selenocysteine oxidation in glutathione peroxidase catalysis: an MS-supported quantum mechanics study. *Free Radic Biol Med* 87: 1–14, 2015.
82. Panfili E, Sandri G, and Ernster L. Distribution of glutathione peroxidases and glutathione reductase in rat brain mitochondria. *FEBS Lett* 290: 35–37, 1991.
83. Pasparakis M and Vandenabeele P. Necroptosis and its role in inflammation. *Nature* 517: 311–320, 2015.
84. Paul BD, Sbodio JJ, Xu R, Vandiver MS, Cha JY, Snowman AM, and Snyder SH. Cystathionine γ -lyase deficiency mediates neurodegeneration in Huntington's disease. *Nature* 509: 96–100, 2014.
85. Praticò D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA, Trojanowski JQ, and Lee VMY. 12/15-Lipoxygenase Is Increased in Alzheimer's Disease. *Am J Pathol* 164: 1655–1662, 2010.
86. Pushpa-Rekha TR, Burdsall AL, Oleksa LM, Chisolm GM, and Driscoll DM. Rat phospholipid-hydroperoxide

- glutathione peroxidase. cDNA cloning and identification of multiple transcription and translation start sites. *J Biol Chem* 270: 26993–26993, 1995.
87. Ran Q, Liang H, Ikeno Y, Qi W, Prolla TA, Roberts LJ, 2nd, Wolf N, Van Remmen H, and Richardson A. Reduction in glutathione peroxidase 4 increases life span through increased sensitivity to apoptosis. *J Gerontol A Biol Sci Med Sci* 62: 932–942, 2007.
 88. Ran Q, Van Remmen H, Gu M, Qi W, Roberts LJ, 2nd, Prolla T, and Richardson A. Embryonic fibroblasts from Gpx4^{+/−} mice: a novel model for studying the role of membrane peroxidation in biological processes. *Free Radic Biol Med* 35: 1101–1109, 2003.
 89. Rapoport SM, Schewe T, Wiesner R, Halangk W, Ludwig P, Janicke-Höhne M, Tannert C, Hiebsch C, and Klatt D. The lipoxygenase of reticulocytes. Purification, characterization and biological dynamics of the lipoxygenase; its identity with the respiratory inhibitors of the reticulocyte. *Eur J Biochem* 96: 545–561, 1979.
 90. Reich HJ and Hondal RJ. Why nature chose selenium. *ACS Chem Biol* 11: 821–841, 2016.
 91. Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K-i, Moriguchi T, Takahashi S, and Bannai S. Redox imbalance in cystine/glutamate transporter-deficient mice. *J Biol Chem* 280: 37423–37429, 2005.
 92. Schilstra MJ, Veldink GA, Verhagen J, and Vliegthart JF. Effect of lipid hydroperoxide on lipoxygenase kinetics. *Biochemistry* 31: 7692–7699, 1992.
 93. Schneider M, Forster H, Boersma A, Seiler A, Wehnes H, Sinowatz F, Neumuller C, Deutsch MJ, Walch A, Hrabe de Angelis M, Wurst W, Ursini F, Roveri A, Maleszewski M, Maiorino M, and Conrad M. Mitochondrial glutathione peroxidase 4 disruption causes male infertility. *Faseb J* 23: 3233–3242, 2009.
 94. Schneider M, Vogt Weisenhorn DM, Seiler A, Bornkamm GW, Brielmeier M, and Conrad M. Embryonic expression profile of phospholipid hydroperoxide glutathione peroxidase. *Gene Expr Patterns* 6: 489–494, 2006.
 95. Schneider M, Wortmann M, Mandal PK, Arpornchayanon W, Jannasch K, Alves F, Strieth S, Conrad M, and Beck H. Absence of glutathione peroxidase 4 affects tumor angiogenesis through increased 12/15-lipoxygenase activity. *Neoplasia* 12: 254–263, 2010.
 96. Schnurr K, Belkner J, Ursini F, Schewe T, and Kühn H. The selenoenzyme phospholipid hydroperoxide glutathione peroxidase controls the activity of the 15-lipoxygenase with complex substrates and preserves the specificity of the oxygenation products. *J Biol Chem* 271: 4653–4658, 1996.
 97. Scott G. *Antioxidants in Science, Technology, Medicine and Nutrition*. Chichester, West Sussex, England: Albion Publishing Limited, 1997, p. 348.
 98. Seiler A, Schneider M, Forster H, Roth S, Wirth EK, Culmsee C, Plesnila N, Kremmer E, Radmark O, Wurst W, Bornkamm GW, Schweizer U, and Conrad M. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. *Cell Metab* 8: 237–248, 2008.
 99. Sengupta A, Lichti UF, Carlson BA, Cattaillon C, Ryscavage AO, Mikulec C, Conrad M, Fischer SM, Hatfield DL, and Yuspa SH. Targeted disruption of glutathione peroxidase 4 in mouse skin epithelial cells impairs post-natal hair follicle morphogenesis that is partially rescued through inhibition of COX-2. *J Invest Dermatol* 133: 1731–1741, 2013.
 100. Sheftel AD, Zhang A-S, Brown C, Shirihai OS, and Ponka P. Direct interorganellar transfer of iron from endosome to mitochondrion. *Blood* 110: 125–132, 2007.
 101. Shi ZZ, Osei-Frimpong J, Kala G, Kala SV, Barrios RJ, Habib GM, Lukin DJ, Danney CM, Matzuk MM, and Lieberman MW. Glutathione synthesis is essential for mouse development but not for cell growth in culture. *Proc Natl Acad Sci U S A* 97: 5101–5106, 2000.
 102. Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, Brown LM, Valenzuela CA, Wolpaw AJ, and Stockwell BR. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. *Nat Chem Biol* 12: 497–503, 2016.
 103. Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A, and Stockwell BR. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. *J Am Chem Soc* 136: 4551–4556, 2014.
 104. Tan S, Schubert D, and Maher P. Oxytosis: a novel form of programmed cell death. *Curr Top Med Chem* 1: 497–506, 2001.
 105. Tang L, Zhang Y, Qian Z, and Shen X. The mechanism of Fe²⁺-initiated lipid peroxidation in liposomes: the dual function of ferrous ions, the roles of the pre-existing lipid peroxides and the lipid peroxy radical. *Biochem J* 352: 27–36, 2000.
 106. Toppo S, Vanin S, Bosello V, and Tosatto SCE. Evolutionary and structural insights into the multifaceted glutathione peroxidase (GPx) superfamily. *Antioxid Redox Signal* 10: 1501–1513, 2008.
 107. Ueta T, Inoue T, Furukawa T, Tamaki Y, Nakagawa Y, Imai H, and Yanagi Y. Glutathione peroxidase 4 is required for maturation of photoreceptor cells. *J Biol Chem* 287: 7675–7682, 2012.
 108. Ursini F, Heim S, Kiess M, Maiorino M, Roveri A, Wissing J, and Flohé L. Dual function of the selenoprotein PHGPx during sperm maturation. *Science* 285: 1393–1396, 1999.
 109. Ursini F, Maiorino M, Hochstein P, and Ernster L. Mitochondrial lipid peroxidation: mechanisms of initiation. The role of iron and iron chelators. *Free Radic Biol Med* 6: 31–36, 1989.
 110. Ursini F, Maiorino M, Valente M, Ferri L, and Gregolin C. Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. *Biochim Biophys Acta* 710: 197–211, 1982.
 111. Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, Lerner CP, and Paigen B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. *J Biol Chem* 278: 25179–25190, 2003.
 112. Wei PC, Hsieh YH, Su MI, Jiang XJ, Hsu PH, Lo WT, Weng JY, Jeng YM, Wang JM, Chen PL, Chang YC, Lee KF, Tsai MD, Shew JY, and Lee WH. Loss of the oxidative stress sensor NPGPx compromises GRP78 chaperone activity and induces systemic disease. *Mol Cell* 48: 1–13, 2012.
 113. Wirth EK, Bharathi BS, Hatfield D, Conrad M, Brielmeier M, and Schweizer U. Cerebellar hypoplasia in mice lacking selenoprotein biosynthesis in neurons. *Biol Trace Elem Res* 158: 203–210, 2014.

114. Wirth EK, Conrad M, Winterer J, Wozny C, Carlson BA, Roth S, Schmitz D, Bornkamm GW, Coppola V, Tessarollo L, Schomburg L, Kohrle J, Hatfield DL, and Schweizer U. Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration. *FASEB J* 24: 844–852, 2010.
115. Wortmann M, Schneider M, Pircher J, Hellfritsch J, Aichler M, Vegi N, Kolle P, Kuhlencordt P, Walch A, Pohl U, Bornkamm GW, Conrad M, and Beck H. Combined deficiency in glutathione peroxidase 4 and vitamin e causes multiorgan thrombus formation and early death in mice. *Circ Res* 113: 408–417, 2013.
116. Yagi K, Komura S, Kojima H, Sun Q, Nagata N, Ohishi N, and Nishikimi M. Expression of human phospholipid hydroperoxide glutathione peroxidase gene for protection of host cells from lipid hydroperoxide-mediated injury. *Biochem Biophys Res Commun* 219: 486–491, 1996.
117. Yagi K, Shidoji Y, Komura S, Kojima H, and Ohishi N. Dissipation of mitochondrial membrane potential by exogenous phospholipid monohydroperoxide and protection against this effect by transfection of cells with phospholipid hydroperoxide glutathione peroxidase gene. *Biochem Biophys Res Commun* 245: 528–533, 1998.
118. Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S, and Stockwell BR. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature* 447: 864–868, 2007.
119. Yamamoto Y and Takahashi K. Glutathione peroxidase isolated from plasma reduces phospholipid hydroperoxides. *Arch Biochem Biophys* 305: 541–545, 1993.
120. Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, and Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. *Proc Natl Acad Sci U S A* 113: E4966–E4975, 2016.
121. Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, and Stockwell BR. Regulation of ferroptotic cancer cell death by GPX4. *Cell* 156: 317–331, 2014.
122. Yang WS and Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, non-apoptotic cell death in oncogenic-RAS-harboring cancer cells. *Chem Biol* 15: 234–245, 2008.
123. Yang WS and Stockwell BR. Ferroptosis: death by lipid peroxidation. *Trends Cell Biol* 26: 165–176, 2015.
124. Yang WS, Yang WS, SriRamaratnam R, SriRamaratnam R, Welsch ME, Welsch ME, Shimada K, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, and Stockwell BR. Regulation of ferroptotic cancer cell death by GPX4. *Cell* 156: 317–331, 2014.
125. Yant LJ, Ran Q, Rao L, Van Remmen H, Shibata T, Belter JG, Motta L, Richardson A, and Prolla TA. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. *Free Radic Biol Med* 34: 496–502, 2003.
126. Yin H, Xu L, and Porter NA. Free radical lipid peroxidation: mechanisms and analysis. *Chem Rev* 111: 5944–5972, 2011.

Address correspondence to:

Prof. Fulvio Ursini
Department of Molecular Medicine
University of Padova
Viale G. Colombo, 3
Padua I-35121
Italy

E-mail: fulvio.ursini@unipd.it

Date of first submission to ARS Central, April 10, 2017; date of acceptance, April 21, 2017.

Abbreviations used

α -TOH = α -tocopherol
 γ -GCS = γ -glutamylcysteine synthetase
 AA = arachidonic acid
 AdA = adrenic acid
 ACSL4 = acyl-CoA synthetase long-chain family member 4
 BSO = L-buthionine sulfoximine
 GS = glutathione synthetase
 GSSG = oxidized glutathione
 cGPx4 = cytosolic form of Glutathione peroxidase 4
 CSE = cystathionine γ -lyase
 mGPx4 = mitochondrial form of Glutathione peroxidase 4
 GPx4 = Glutathione peroxidase 4
 GSH = reduced glutathione
 HNE = 4-hydroxynonenal
 HO = heme oxygenase-1
 IMS = intermembrane space of mitochondria
 LIP = labile iron pool
 LOX = lipoxygenase
 LPCAT3 = lysophosphatidylcholine acyltransferase 3
 PE = phosphatidylethanolamine
 PHGPx = Phospholipid Hydroperoxide Glutathione Peroxidase
 P.I.P. = peroxidation inhibiting protein
 PL = phospholipid containing polyunsaturated fatty acid(s)
 PL', PL'' = distinct membrane phospholipids containing polyunsaturated fatty acid(s)
 PL $\bullet$ = phospholipid containing a fatty acid carbon centered radical
 PLO $\bullet$ = phospholipid containing a alkoxyl radical derivative of a fatty acid
 PLOH = phospholipid containing a hydroxyl derivative of a fatty acid
 PLOO $\bullet$ = phospholipid containing a hydroperoxyl radical derivative of a fatty acid
 PLOOH = phospholipid hydroperoxide, a phospholipid containing a hydroperoxyl derivative of a fatty acid
 SOD = superoxide dismutase(s)
 TXNRD1 = thioredoxin reductase 1
 X $\bullet$ = unspecified free radical